- Home
- GIGM vs PRPH Comparison
GIGM vs PRPH Comparison
Compare GIGM & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- PRPH
- Stock Information
- Founded
- GIGM 1998
- PRPH 1989
- Country
- GIGM Taiwan
- PRPH United States
- Employees
- GIGM N/A
- PRPH N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- PRPH Health Care
- Exchange
- GIGM Nasdaq
- PRPH Nasdaq
- Market Cap
- GIGM 16.1M
- PRPH 17.7M
- IPO Year
- GIGM 2000
- PRPH 1997
- Fundamental
- Price
- GIGM $1.55
- PRPH $0.28
- Analyst Decision
- GIGM
- PRPH
- Analyst Count
- GIGM 0
- PRPH 0
- Target Price
- GIGM N/A
- PRPH N/A
- AVG Volume (30 Days)
- GIGM 6.8K
- PRPH 1.1M
- Earning Date
- GIGM 07-31-2025
- PRPH 08-13-2025
- Dividend Yield
- GIGM N/A
- PRPH N/A
- EPS Growth
- GIGM N/A
- PRPH N/A
- EPS
- GIGM N/A
- PRPH N/A
- Revenue
- GIGM $3,250,000.00
- PRPH $5,845,000.00
- Revenue This Year
- GIGM N/A
- PRPH $221.82
- Revenue Next Year
- GIGM N/A
- PRPH N/A
- P/E Ratio
- GIGM N/A
- PRPH N/A
- Revenue Growth
- GIGM N/A
- PRPH N/A
- 52 Week Low
- GIGM $1.30
- PRPH $0.22
- 52 Week High
- GIGM $1.80
- PRPH $3.00
- Technical
- Relative Strength Index (RSI)
- GIGM 59.00
- PRPH 35.31
- Support Level
- GIGM $1.42
- PRPH $0.30
- Resistance Level
- GIGM $1.56
- PRPH $0.35
- Average True Range (ATR)
- GIGM 0.07
- PRPH 0.04
- MACD
- GIGM 0.01
- PRPH -0.01
- Stochastic Oscillator
- GIGM 71.05
- PRPH 1.93
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.